Company Overview
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophilin-2 (PKP2) gene to cardiac muscle for the treatment of PKP2-ACM; and LX2021, a gene therapy candidate, which is in preclinical trial to deliver the coding sequence for the functional connexin 43, or Cx43, protein for a group of inherited cardiac muscle disorders associated with a high risk of sudden death, including arrhythmogenic cardiomyopathy (ACM) and certain forms of dilated cardiomyopathy. The company is also developing LX2022, a gene therapy candidate, which is in preclinical trial to deliver a functional TNNI3 gene to myocardial cells to treat a distinct form of hypertrophic cardiomyopathy. In addition, it is developing LX1001, LX1020, and LX1021, an AAVrh10-based gene therapy candidate, which has completed phase 1/2 clinical trial for the treatment of APOE4-associated Alzheimer's disease. The company has a license agreement with Cornell University to conduct the Phase 1/2 clinical trial of LX1001, as well as support the development of the LX1004 program; a research collaboration agreement with Cornell University to conduct preclinical research to develop the licensed technology; and third license agreement which obtained certain rights for FA cardiomyopathy, including rights to current and future clinical data from an ongoing Cornell University investigator-initiated Phase 1A trial of a gene therapy candidate. The company was founded in 2017 and is headquartered in New York, New York.
Growth & Price Performance
Stock Price Performance
| 1 Year: | +4.05% |
| 6 Months: | -56.17% |
| 3 Months: | -27.59% |
| 1 Month: | +10.00% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)45.60 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 56.5% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | LXEO Lexeo Therapeutics, Inc. R2K | 4.62 | -4.12 | $362.77M | 0.00% | -43.38% | -54.75% | - | - |
| 2 | LLY Eli Lilly and Company SPX | 1,152.54 | 41.02 | $1.03T | 0.61% | - | 107.46% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPX | 253.85 | 29.45 | $611.07B | 2.23% | 14.88% | 26.42% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPX | 244.78 | 119.40 | $432.48B | 3.04% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | UNH UnitedHealth Group Incorporated SPX | 425.19 | 32.02 | $386.13B | 2.27% | 9.74% | 12.18% | 10.40% | 5.43% |
| 6 | MRK Merck & Co., Inc. SPX | 120.78 | 34.02 | $298.31B | 2.86% | - | 18.94% | 5.64% | 10.01% |
| 7 | AZN AstraZeneca PLC NDX | 164.50 | 24.81 | $255.12B | 1.77% | 15.97% | 23.48% | 9.82% | 45.96% |
| 8 | TMO Thermo Fisher Scientific Inc. SPX | 534.07 | 29.33 | $198.47B | 0.40% | 8.14% | 13.52% | 8.81% | 12.95% |
| 9 | AMGN Amgen Inc. NDXSPX | 355.25 | 24.69 | $191.73B | 2.84% | 18.02% | 101.32% | 11.77% | 5.58% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | 531.00K | - | - | - | - | - | - | - | - | - | - |
| Operating Income | - | - | -17.48M | -19.29M | -13.97M | -20.27M | -23.29M | -23.55M | -31.54M | -33.80M | -30.69M | -21.65M | -22.33M |
| Net Income | -12.50M | -15.14M | -17.05M | -18.66M | -13.44M | -20.11M | -21.68M | -21.24M | -29.49M | -32.66M | -26.10M | -20.28M | -20.20M |
| Diluted EPS | - | - | -10.38 | -11.58 | -8.30 | -12.36 | -0.77 | -0.64 | -0.89 | -0.99 | -0.60 | -0.33 | -0.25 |
| R&D Expense | - | - | 15.36M | 16.44M | 11.24M | 17.25M | 15.74M | 16.56M | 23.42M | 17.17M | 14.72M | 15.70M | 15.70M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Revenue | 654.00K | - | - | - |
| Operating Income | -60.51M | -68.51M | -105.77M | -109.26M |
| Net Income | -59.28M | -66.39M | -98.33M | -99.96M |
| Diluted EPS | -36.36 | -12.40 | -3.09 | -1.86 |
| R&D Expense | 49.16M | 53.13M | 74.09M | 63.80M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|
| Total Assets | - | 97.08M | 139.81M | 146.94M | 268.69M |
| Total Equity | -55.60M | -112.95M | 113.53M | 116.84M | 246.67M |
| Cash & Equivalents | 135.86M | 77.33M | 121.47M | 35.01M | 63.00M |
| Total Liabilities | - | 25.00M | 26.27M | 30.10M | 22.02M |
| Current Liabilities | - | 14.35M | 17.24M | 22.85M | 16.81M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Operating Cash Flow | -54.56M | -59.50M | -81.15M | -98.56M |
| Investing Cash Flow | -901.00K | -165.00K | -94.08M | -90.25M |
| Financing Cash Flow | 189.00K | 103.79M | 88.78M | 216.79M |
| Capital Expenditure | -672.00K | -115.00K | -481.00K | -397.00K |
| Free Cash Flow | -55.23M | -59.61M | -81.63M | -98.96M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|
| Gross Margin % | - | - | - | - |
| Operating Margin % | -9,252.1% | - | - | - |
| Net Margin % | -9,063.8% | - | - | - |
| ROE % | 52.5% | -58.5% | -84.2% | -40.5% |
| ROCE % | -73.1% | -55.9% | -85.2% | -43.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Paradigm Biocapital Advisors LP | 7.88% | 6.18M | $28.76M |
| 2 | Blackrock Inc. | 6.51% | 5.11M | $23.77M |
| 3 | Affinity Asset Advisors, Llc | 6.43% | 5.05M | $23.48M |
| 4 | RA Capital Management, L.P. | 6.37% | 5.00M | $23.25M |
| 5 | Janus Henderson Group PLC | 6.34% | 4.98M | $23.14M |
| 6 | Vestal Point Capital, LP | 5.70% | 4.47M | $20.81M |
| 7 | Frazier Life Sciences Management, L.P. | 5.64% | 4.42M | $20.57M |
| 8 | Citadel Advisors Llc | 4.88% | 3.83M | $17.83M |
| 9 | Orbimed Advisors LLC. | 4.59% | 3.60M | $16.75M |
| 10 | State Street Corporation | 4.54% | 3.57M | $16.59M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for LXEO
LXEO News | LEXEO THERAPEUTICS INC (NASDAQ:LXEO) - ChartMill
<a href="https://news.google.com/rss/articles/CBMiW0FVX3lxTE9iWF9fU0R0WFZ5VGJIY25yLWpvSjQzQU5MTzdCR3JhYUxObUpZem11TjFsWFlqdkVvUGRFLV9JcHB4NS1sR2NMNWhhOHRnY29YNjRSY2gxdHNfNWM?oc=5" target="_blank">LXEO News | LEXEO THERAPEUTICS INC (NASDAQ:L…
Is Lexeo Therapeutics, Inc. (LXEO) Stock Still a Gene Therapy Opportunity After Analyst Valuation Update? - Yahoo Finance
<a href="https://news.google.com/rss/articles/CBMimgFBVV95cUxQQTd2T1VGRzJYVzBOQUVtMldwaDhaUVhiQ28xU2Zsd21mVHBCeTVZeHVuamU5UVBoeG1uaHAtVXQxYi10dDB2NU9YWFJPNjNGWUVndVQ1b1NrTU0yVEUwTXdGLWcyeVpKX3hrSXptWWMxNXo1NXFENHF3b2Qxd0thaVUyc3MwYnR1MWR2VT…
Lexeo Therapeutics COO Otero sells $20,903 in LXEO stock - Investing.com
<a href="https://news.google.com/rss/articles/CBMiuwFBVV95cUxNNHYxOHBrS3RsWElZN2I3blFtNjFUUEo4dkNTZG56X3d6V1JmZFZqQjBCUEhQLVJJNDdpMXNQS1pCcjVDVnhjek5rLUpaTGVKalI3T2ZkYzI2LVBodThkY1FlMUcxN2VtRDJQWUVvN25oNTE3WnZ6b1hSZURJTUp5RUdZalZBUmJTaFZEdF…
LXEO Forecast — Price Target — Prediction for 2027 - TradingView
<a href="https://news.google.com/rss/articles/CBMiekFVX3lxTE1iQUpRbnA2dHpRSm4yOXBMRTdYU2FvVXQ1WG5QQ0k1MTBoNlE2cFRKd21uTHZfN3JIQ1c4RTd0UDRobjZaaVc4VWl0N3AtTnBFRWkxZktVQ0JSTktjOHZKZ1dJNThFcjliQm9ILS10ekZ3U19UM1QyanZ3?oc=5" target="_blank">LXE…
Insider Sale: Chief Financial Officer of $LXEO Sells 4,641 Shares - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMipwFBVV95cUxORlVvenBWdElfaDRuNHg5M1dNSVF2OWx6dml6WDUxMWNjUmQzQ09qSV9vOVZpZ1FYRFNNcU5xdkR3Nkd3WmdJSkJKWUl6LTVUNjVmTnpoUlJWZmJTNjNmaFNxZWthamtzVFZZcm1XalI3Q2xWN1dqQUpOMjdDN2hYVDg3Y1ZOdVF2eXZwb3…
Lexeo Therapeutics (LXEO) director awarded options on 35,000 shares at $4.70 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMitwFBVV95cUxON3FPWFZfTGhhaUlGNWlsTEpOdXNwNjc4SDJBUE5MaUZ6UHpDbXlpUE9HNXNvajVfeUMxbGlkQXM1RmYzdkRmY1V1MDdfbDh5clBWMGhPcXdSR2xBRlprcHNpaGNGTURodU1FN2tJd1FOV1pUdzdqRXJrMWFLcXY2ZksxNHJKV3lTNlZBOV…
LXEO — Frequently Asked Questions
What is the current share price of Lexeo Therapeutics, Inc. (LXEO)?
As of 2026-07-14 21:23 PDT, Lexeo Therapeutics, Inc. (LXEO) trades at $4.62 on NasdaqGM. Its 52-week range is $3.67 to $10.63.
What is the market capitalisation of LXEO?
Lexeo Therapeutics, Inc. (LXEO) has a market capitalisation of $362.77M on NasdaqGM.
What is the P/E ratio of LXEO?
LXEO trades at a trailing price-to-earnings (P/E) ratio of -4.12. The industry average P/E is 25.41. Its price-to-book (P/B) ratio is 1.40.
What is the return on equity (ROE) of LXEO?
LXEO has a return on equity (ROE) of -54.75%. Its return on capital employed (ROCE) is -43.38%.
Is LXEO a good stock to buy?
This page provides a data-driven analysis of Lexeo Therapeutics, Inc. (LXEO), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.